SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as investors scrutinize its growth trajectory versus digital-first competitors like Robinhood, alongside ongoing community frustration regarding trading restrictions and interface transitions. Market participants are also keeping a close watch on upcoming earnings reports as the firm attempts to balance its legacy business model with increased demand for modern brokerage features.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing intense downward pressure driven by concerns over mounting legal challenges, including a lawsuit from the NCAA, and broader industry debates surrounding the regulation of prediction markets. Investors are actively debating the stock's future, with many on community forums expressing bearish sentiment and a preference for shorting the shares amid ongoing insider selling and heightened competition.

Mask Network is the core product of Dimension, which is positioned to become the bridge that connects internet users from Web 2.0 to Web 3.0. The foundational technology of Mask Network is a peer-to-peer encrypted messaging application, with new functions continuously being created around this foundation. We at Mask Network are strong believers in the ownership economy. People should own what they produce, people should own their data, their attention and the virtual space they choose to contribute to.  Mask Network integrates decentralized social messaging, borderless payment network, and decentralized file storage and sharing to provide a safe and convenient portal for users to jump right into the continent of decentralized finance and then the new world of Web 3.0.

Mask Network

Mask Network is trending as investors capitalize on its extreme low-float status following a recent reverse split, sparking comparisons to historical micro-cap runners. The community is actively monitoring technical setups and liquidity for potential momentum swings, while enthusiasm remains high regarding its position in the AI and Web3 infrastructure space.

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Journey Medical Corp

Journey Medical Corp is experiencing high community interest following the FDA approval of Emrosi, with investors keenly focused on the upcoming commercialization strategy and potential for profitability in 2025. Discussion is currently centered on insurance coverage expectations, the upcoming commercialization conference call, and the belief that the stock is undervalued given its potential to capture significant market share from existing rosacea treatments.

Karman Holdings, Inc. engages in the design, testing, manufacturing, and sale of dependable missile systems. It offers Payload Protection & Deployment Systems, Aerodynamic Interstage Systems, and Propulsion Systems. The company was founded on August 20, 2020 and is headquartered in Huntington Beach, CA.

Karman Holdings Inc.

Karman Holdings Ord Shs

Karman Holdings is generating significant interest after reporting strong quarterly results and raising its revenue and EBITDA guidance, fueling optimism around its role in hypersonic defense and the munitions "super cycle." While some investors express caution regarding the stock's valuation and the impact of its recent expansion through acquisitions, the community remains bullish on its long-term fundamentals and potential as a critical player in national defense.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant attention from investors anticipating a potential IPO for SpaceX, with many market participants viewing the fund as a strategic proxy to gain exposure to high-growth, venture-backed companies like OpenAI and SpaceX. Community discussions are heavily focused on the fund's premium-to-NAV volatility compared to similar holdings, while bulls argue the potential for a massive, IPO-driven price squeeze makes it a compelling, albeit speculative, swing play.

Jefferies Financial Group, Inc. is a holding company, which engages in the provision of financial services. It operates through Investment Banking and Capital Markets, and Asset Management. The Investment Banking and Capital Markets segment involves the provision of underwriting and financial advisory services in the Americas, Europe and the Middle East, and Asia-Pacific. The Asset Management segment includes investing seed and additional strategic capital. The company was founded in 1968 and is headquartered in New York, NY.

Jefferies Financial Group Inc

Jefferies Financial Group is trending as investors weigh potential takeover interest from Sumitomo Mitsui Financial Group (SMFG), which has fueled speculation despite reports that no immediate plans exist. The community remains focused on the company's role as a bellwether for investment banking and capital markets, while debate continues over its exposure to recent private credit defaults and legal challenges.

Polywhale

Investors are actively driving social sentiment for Krill within the decentralized finance space, leading to speculative community discussions comparing the asset to other marine-themed tokens in the sector.

ORCASM is a filthy little memecoin that knows exactly what you came for. It launched on Orca's Wavebreak but was born to make waves—wet, loud, and unforgettable. This isn’t your ordinary meme. ORCASM builds up the tension slow, goes deep, and leaves you gasping for more. It’s raw, unfiltered trencher energy dripping with shameless satisfaction. No promises. No roadmaps. Just pure, orcasmic pleasure.

Orcasm

Orcasm is surging as the latest marine-themed meme coin, drawing intense community focus as traders pivot away from traditional animal-based assets. While supporters celebrate a high-velocity rally driven by whale-watching sentiment, skeptics remain vocal, warning of typical high-risk market volatility and potential pump-and-dump mechanics.

Navan, Inc. engages in offering a cloud-based technology platform for travelers. Its products include business travel and expense management. The company was founded by Ariel Cohen and Ilan Twig in February 2015 and is headquartered in Palo Alto, CA.

Navan Inc. - Ordinary Shares - Class A

Navan shares are experiencing high volatility as investors weigh strong revenue growth and AI platform integration against concerns regarding profitability and recent insider selling. While some community members view the stock as a long-term play on travel disruption, others remain skeptical about its valuation and post-IPO performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dermata Therapeutics Announces A Private Placement Valued At Up To $12.4 Mln

(RTTNews) - Dermata Therapeutics Inc. (DRMA), a dermatologic firm, announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2.02 million shares of common...

Why Is Dermata Therapeutics Stock Surging Wednesday?

Dermata Therapeutics rose after announcing a private placement offering of common shares, Series C warrants, and Series D warrants.read more...

<ul class="summary-bullets"><li>The offering, alongside two series of warrants that permit future purchases of the same amount of shares, is priced at $2.04 per unit.&nbsp;</li><li>The company plans to use the proceeds for general corporate needs, including consumer research and rollout activities for its forthcoming over‑the‑counter acne kit.</li><li>In early December, Dermata said it is preparing to launch a fresh brand identity for its over-the-counter skincare line.</li></ul>Dermata Therapeutics, Inc. (DRMA) stock surged 22% in Wednesday’s premarket after the company announced that it has struck definitive agreements to issue roughly 2.02 million shares of its common stock in a private placement deal.&nbsp;The offering, alongside two series of warrants that permit future purchases of the same amount of shares, is priced at $2.04 per unit.&nbsp;<h2 class="st-heading-2">Use Of Proceeds</h2>Dermata expects roughly $4.1 million in gross proceeds initially, before fees and expenses. If all new warrants are exercised for cash, the number could rise by approximately $8.3 million, bringing total potential funding to nearly $12.4 million.&nbsp;The company plans to use the proceeds for general corporate needs, including consumer research, rollout activities for its forthcoming over‑the‑counter acne kit, licensing initiatives, possible strategic investments, and working capital.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/DRMA">Dermata Therapeutics’ stock</a> traded over 24% higher in Wednesday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. At the same time, message volume shifted to ‘extremely high’ from ‘extremely low’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:934/106;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_24_084540_png_7928eb6a71.webp" alt="DRMA’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Dec. 24, 2025 | Source: Stocktwits" width="934" height="106"><figcaption>DRMA’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Dec. 24, 2025 | Source: Stocktwits</figcaption></figure>Dermata creates science-based skin treatments with a focus on over-the-counter (OTC) skin products.&nbsp;<h2 class="st-heading-2">Dermata’s&nbsp;Skincare Line</h2>In early December, the company said it is preparing to launch a fresh brand identity for its over-the-counter skincare line, signaling a move toward a science-driven, direct-to-consumer model.&nbsp;Central to the rebrand is Dermata’s proprietary Spongilla technology, which is expected to enhance the efficacy of routine skincare. By simplifying regimens and boosting results, the products are designed to amplify the overall effectiveness of a skincare routine.The latest funding strategy with a fresh financing move is aimed at extending the runway for the company’s upcoming consumer skin‑care initiatives.&nbsp;DRMA stock has declined 84% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intel-s-manufacturing-push-faces-fresh-test-after-nvidia-passes-on-18-a-chips-report/cLesu73REv4">Intel’s Manufacturing Push Faces Fresh Test After Nvidia Passes On 18A Chips: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Dermata Therapeutics Stock Surge 22% Pre-Market Today?

The company has entered into definitive agreements to issue roughly 2.02 million shares of its common stock in a private placement deal. 

Equity

The company has entered into definitive agreements to issue roughly 2.02 million shares of its common stock in a private placement deal. 


Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.54	--	--	N/A
Q3 '25	-$1.59	-$1.65	-3.77%	MISSED
Q2 '25	-$2.90	-$1.66	42.76%	BEAT
Q1 '25	-$0.45	-$4.50	-900.00%	MISSED
Q4 '24	-$1.50	-$1.34	10.67%	BEAT

DRMA
Dermata Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest DRMA News

DRMADermata Therapeutics Inc